EXEL: Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in RET-Rearranged Non-Small Cell Lung Cancers

New alert via PocketInfo for EXEL:

Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in RET-Rearranged Non-Small Cell Lung Cancers

Press Releases: http://www.exelixis.com/investors-media/press-releases
SEC Filings: http://www.exelixis.com/investors-media/sec-filings
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8